ERBB2 and neoplasm: Significant differences in DRFS (p = 0.006) and OS (p = 0.006) were observed among patients with different tumor molecular subtypes (Fig. 3a, b), the group of patients with luminal A or luminal B/HER2-negative tumors showing a better prognosis.